Lin Yu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lin Yu has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
- Chunmeng Wang
Department of Musculoskeletal Oncology, Bone and Soft Tissue Sarcomas Centre , Fudan University Shanghai Cancer Centre , Fudan University , Shanghai , China , fudan.edu.cn
15 shared publications - Wangjun Yan
Department of musculoskeletal Oncology Fudan University Shanghai Cancer Center Shanghai China
15 shared publications - Yong Chen
Department of Musculoskeletal Oncology, Fudan University Shanghai Cancer Center, Shanghai, China
15 shared publications - Yu Xu
Department of Musculoskeletal Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China
15 shared publications - Jian Wang
Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China
13 shared publications - Xiaowei Zhang
Department of Medical Oncology Fudan University Shanghai Cancer Center Shanghai China
10 shared publications
Latest Publications
- 13 October 2026
- Published by Wiley in Histopathology
Alveolar soft part sarcoma of the female genital tract: a clinicopathological and molecular genetic study of 26 cases
Aims: Occurrence of alveolar soft part sarcoma (ASPS) in the female genital tract is extremely rare. We report 26 cases of ASPS arising in the female genital tract to further characterize its clinicopathological and molecular features, differential diagnosis and biological behaviour. Methods and results: Twenty‐six cases of ASPS in the female genital tract were retrieved from our pathology archives. Patient age ranged from 11 to 69 years (median = 30 years). Tumours involved the uterus ( n = 22), vagina ( n = 3), and broad ligament ( n = 1), with a median size of 3.3 cm (1.5–8.5 cm). Histologically, the tumours were predominantly composed of large epithelioid or round cells with abundant eosinophilic‐to‐clear cytoplasm, round nuclei and prominent nucleoli. Architecturally, tumour cells were arranged mostly in diffuse sheets or solid nests, while classic pseudoalveolar structures were rarely observed. All tumours showed strong TFE3 nuclear expression (100%), with variable immunoreactivity for ER (10/11, 90.9%) and PR (9/9, 100%). Twenty‐one tested tumours demonstrated TFE3 rearrangement or ASPSCR1::TFE3 fusion by fluorescence in situ hybridization or targeted RNA sequencing. Among 21 patients’ available follow‐up data (range, 17–151 months; median, 30 months), 2 of 3 vaginal ASPS patients developed disease progression (1 local recurrence, 1 lung metastasis), whereas all 18 patients with uterine ASPS (range = 17–151 months; median = 30.5 months) remained disease‐free. Conclusions: Female genital tract ASPS most commonly affects the uterus of young women. Uterine ASPS may have a relatively favourable prognosis. Distinguishing ASPS from its morphological mimickers, especially perivascular epithelioid cell tumour (PEComa), is of clinical importance to avoid inappropriate treatment and inaccurate prognosis assessment.
- 13 October 2026
- Published by Wiley in Histopathology
Alveolar soft part sarcoma of the female genital tract: a clinicopathological and molecular genetic study of 26 cases
Aims: Occurrence of alveolar soft part sarcoma (ASPS) in the female genital tract is extremely rare. We report 26 cases of ASPS arising in the female genital tract to further characterize its clinicopathological and molecular features, differential diagnosis and biological behaviour. Methods and results: Twenty‐six cases of ASPS in the female genital tract were retrieved from our pathology archives. Patient age ranged from 11 to 69 years (median = 30 years). Tumours involved the uterus ( n = 22), vagina ( n = 3), and broad ligament ( n = 1), with a median size of 3.3 cm (1.5–8.5 cm). Histologically, the tumours were predominantly composed of large epithelioid or round cells with abundant eosinophilic‐to‐clear cytoplasm, round nuclei and prominent nucleoli. Architecturally, tumour cells were arranged mostly in diffuse sheets or solid nests, while classic pseudoalveolar structures were rarely observed. All tumours showed strong TFE3 nuclear expression (100%), with variable immunoreactivity for ER (10/11, 90.9%) and PR (9/9, 100%). Twenty‐one tested tumours demonstrated TFE3 rearrangement or ASPSCR1::TFE3 fusion by fluorescence in situ hybridization or targeted RNA sequencing. Among 21 patients’ available follow‐up data (range, 17–151 months; median, 30 months), 2 of 3 vaginal ASPS patients developed disease progression (1 local recurrence, 1 lung metastasis), whereas all 18 patients with uterine ASPS (range = 17–151 months; median = 30.5 months) remained disease‐free. Conclusions: Female genital tract ASPS most commonly affects the uterus of young women. Uterine ASPS may have a relatively favourable prognosis. Distinguishing ASPS from its morphological mimickers, especially perivascular epithelioid cell tumour (PEComa), is of clinical importance to avoid inappropriate treatment and inaccurate prognosis assessment.
- 22 April 2026
- Published by Wiley in Histopathology
- Vol. 89 (2) , 278-290
PLAG1 ‐rearranged uterine mesenchymal tumours: A study of 11 cases showing distinct histological features beyond myxoid morphology
Aims: PLAG1 gene fusions have been identified in a subset of uterine sarcomas and were historically associated with myxoid morphology. However, recent evidence shows that not all cases demonstrate myxoid features or conventional smooth muscle immunophenotype. Herein, we present 11 cases of PLAG1‐rearranged uterine mesenchymal tumours to further characterize their clinicopathologic, immunohistochemical and molecular profiles. Methods: Eleven cases of PLAG1 ‐rearranged uterine mesenchymal tumours were included from Fudan University Shanghai Cancer Center, comprising nine consultation referrals and two primary diagnoses. Clinicopathological features were reviewed, and all cases underwent targeted RNA sequencing with a 631‐gene panel. Results: The median patient age was 43 years (range: 31–58). Tumours occurred in the uterine corpus ( n = 10) or broad ligament ( n = 1), with a median size of 10 cm (range: 5.8–19 cm). Most presented at FIGO stage I. During follow‐up, 27.3% (3/11) of patients developed recurrence or metastasis. Histologic evaluation revealed significant heterogeneity: myxoid morphology in 54.5% (6/11), epithelioid morphology in 27.3% (3/11) and spindle cell morphology in 18.2% (2/11). Immunohistochemically, 81.8% (9/11) expressed at least one smooth muscle marker (desmin, h‐caldesmon or SMA). RNA sequencing confirmed PLAG1 rearrangements with multiple partners, including RAB2A , TRPS1 , PBX1 , PRLR , BOC , CSDE1 , TMEM68 , PHLPP1 , UBC , ESPL1 and NCOR2 . The most frequent fusions were TRPS1::PLAG1 (27.3%, n = 3) and CSDE1::PLAG1 (18.2%, n = 2). Conclusion: PLAG1 ‐rearranged uterine mesenchymal tumours demonstrate notable morphologic heterogeneity, predominantly presenting as myxoid leiomyosarcoma. We recommend using the integrated diagnostic term ‘ PLAG1 ‐rearranged uterine mesenchymal tumour with features of [specific morphology]’ to capture both the genetic alteration and histologic spectrum, accompanied by a comment regarding the limited experience and potential for recurrence.
- 22 April 2026
- Published by Wiley in Histopathology
- Vol. 89 (2) , 278-290
PLAG1 ‐rearranged uterine mesenchymal tumours: A study of 11 cases showing distinct histological features beyond myxoid morphology
Aims: PLAG1 gene fusions have been identified in a subset of uterine sarcomas and were historically associated with myxoid morphology. However, recent evidence shows that not all cases demonstrate myxoid features or conventional smooth muscle immunophenotype. Herein, we present 11 cases of PLAG1‐rearranged uterine mesenchymal tumours to further characterize their clinicopathologic, immunohistochemical and molecular profiles. Methods: Eleven cases of PLAG1 ‐rearranged uterine mesenchymal tumours were included from Fudan University Shanghai Cancer Center, comprising nine consultation referrals and two primary diagnoses. Clinicopathological features were reviewed, and all cases underwent targeted RNA sequencing with a 631‐gene panel. Results: The median patient age was 43 years (range: 31–58). Tumours occurred in the uterine corpus ( n = 10) or broad ligament ( n = 1), with a median size of 10 cm (range: 5.8–19 cm). Most presented at FIGO stage I. During follow‐up, 27.3% (3/11) of patients developed recurrence or metastasis. Histologic evaluation revealed significant heterogeneity: myxoid morphology in 54.5% (6/11), epithelioid morphology in 27.3% (3/11) and spindle cell morphology in 18.2% (2/11). Immunohistochemically, 81.8% (9/11) expressed at least one smooth muscle marker (desmin, h‐caldesmon or SMA). RNA sequencing confirmed PLAG1 rearrangements with multiple partners, including RAB2A , TRPS1 , PBX1 , PRLR , BOC , CSDE1 , TMEM68 , PHLPP1 , UBC , ESPL1 and NCOR2 . The most frequent fusions were TRPS1::PLAG1 (27.3%, n = 3) and CSDE1::PLAG1 (18.2%, n = 2). Conclusion: PLAG1 ‐rearranged uterine mesenchymal tumours demonstrate notable morphologic heterogeneity, predominantly presenting as myxoid leiomyosarcoma. We recommend using the integrated diagnostic term ‘ PLAG1 ‐rearranged uterine mesenchymal tumour with features of [specific morphology]’ to capture both the genetic alteration and histologic spectrum, accompanied by a comment regarding the limited experience and potential for recurrence.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from Pegylated Liposomal Doxorubicin Combined with Ifosfamide for Treating Advanced or Metastatic Soft-tissue Sarcoma: A Prospective, Single-arm Phase II Study
Figure S1. No significant change was observed in LVEF at baseline and after treatment (p=0.669, Kruskal-Wallis rank sum test).
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Pegylated Liposomal Doxorubicin Combined with Ifosfamide for Treating Advanced or Metastatic Soft-tissue Sarcoma: A Prospective, Single-arm Phase II Study
Figure S1. No significant change was observed in LVEF at baseline and after treatment (p=0.669, Kruskal-Wallis rank sum test).
- Open Access
- 1 August 2025
- Published by Elsevier in Human Pathology Reports
- Vol. 41
Primary esophageal succinate dehydrogenase deficient epithelioid gastrointestinal stromal tumor: A diagnostic pitfall of poorly differentiated carcinoma
- 1 August 2025
- Published by Elsevier in Human Pathology Reports
- Vol. 41
Open AccessPrimary esophageal succinate dehydrogenase deficient epithelioid gastrointestinal stromal tumor: A diagnostic pitfall of poorly differentiated carcinoma
- Open Access
- 15 April 2025
- Published by Wiley in Clinical and Translational Medicine
- Vol. 15 (4) , e70308
Fruquintinib as first‐line or second‐line treatment in unresectable or metastatic soft‐tissue sarcoma: A prospective, single‐arm phase II study
- 15 April 2025
- Published by Wiley in Clinical and Translational Medicine
- Vol. 15 (4) , e70308
Open AccessFruquintinib as first‐line or second‐line treatment in unresectable or metastatic soft‐tissue sarcoma: A prospective, single‐arm phase II study
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Anlotinib versus Placebo as Adjuvant Therapy for Localized High-Grade Soft-Tissue Sarcomas: A Phase II, Double-Blinded, Randomized Controlled Trial
Supplementary Table S2. Characteristics of patients with resected undifferentiated pleomorphic sarcoma (UPS) in the real-world report.
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Anlotinib versus Placebo as Adjuvant Therapy for Localized High-Grade Soft-Tissue Sarcomas: A Phase II, Double-Blinded, Randomized Controlled Trial
Supplementary Table S2. Characteristics of patients with resected undifferentiated pleomorphic sarcoma (UPS) in the real-world report.
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Anlotinib versus Placebo as Adjuvant Therapy for Localized High-Grade Soft-Tissue Sarcomas: A Phase II, Double-Blinded, Randomized Controlled Trial
Supplementary Figure S1. Kaplan-Meier Curve showing the 1-year real-world recurrence-free survival (rwRFS) rate in UPS patients with and without adjuvant anlotinib therapy.
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Anlotinib versus Placebo as Adjuvant Therapy for Localized High-Grade Soft-Tissue Sarcomas: A Phase II, Double-Blinded, Randomized Controlled Trial
Supplementary Figure S1. Kaplan-Meier Curve showing the 1-year real-world recurrence-free survival (rwRFS) rate in UPS patients with and without adjuvant anlotinib therapy.
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Data from Anlotinib versus Placebo as Adjuvant Therapy for Localized High-Grade Soft-Tissue Sarcomas: A Phase II, Double-Blinded, Randomized Controlled Trial
Purpose:We aimed to investigate the efficacy and safety of anlotinib as adjuvant targeted therapy for completely resected localized high-grade soft-tissue sarcomas (STS).Patients and Methods:Patients with localized high-grade STS after complete resection were randomly assigned in a 1:1 ratio to receive either oral 12 mg anlotinib or placebo once daily on days 1 to 14 every 21 days as a cycle, with up to six cycles until disease relapse, unmanageable toxicity, or death. The efficacy and safety were analyzed. This trial was the first trial exploring adjuvant targeted therapy for STS (NCT03951571).Results:Between June 2019 and November 2023, 88 patients were randomly assigned to receive anlotinib (n = 44) or placebo (n = 44). With a median follow-up of 30.95 months, the 1- and 2-year disease-free survival rates were 88% and 77% in the anlotinib group compared with 64% and 58% in the placebo group, respectively. Compared with patients treated with surgery alone, patients receiving adjuvant anlotinib combined with surgery had a reduced risk of disease recurrence [HR, 0.47; 95% confidence interval (CI), 0.22–1.00; P = 0.0445]. Based on the tumor histology, the reduced risk of disease recurrence with anlotinib versus placebo was observed in patients with myxofibrosarcoma (HR, 0.54; 95% CI, 0.17–1.65; P = 0.2698) and undifferentiated pleomorphic sarcoma (HR, 0.58; 95% CI, 0.12–2.87; P = 0.4971). Four patients discontinued anlotinib: two for proteinuria/hematuria (2/44, 5%) and two for poor healing of surgical wound (2/44, 5%).Conclusions:Compared with surgery alone, adjuvant anlotinib following surgery reduces the incidence of disease relapse in localized high-grade STS, with acceptable toxicity.
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Anlotinib versus Placebo as Adjuvant Therapy for Localized High-Grade Soft-Tissue Sarcomas: A Phase II, Double-Blinded, Randomized Controlled Trial
Purpose:We aimed to investigate the efficacy and safety of anlotinib as adjuvant targeted therapy for completely resected localized high-grade soft-tissue sarcomas (STS).Patients and Methods:Patients with localized high-grade STS after complete resection were randomly assigned in a 1:1 ratio to receive either oral 12 mg anlotinib or placebo once daily on days 1 to 14 every 21 days as a cycle, with up to six cycles until disease relapse, unmanageable toxicity, or death. The efficacy and safety were analyzed. This trial was the first trial exploring adjuvant targeted therapy for STS (NCT03951571).Results:Between June 2019 and November 2023, 88 patients were randomly assigned to receive anlotinib (n = 44) or placebo (n = 44). With a median follow-up of 30.95 months, the 1- and 2-year disease-free survival rates were 88% and 77% in the anlotinib group compared with 64% and 58% in the placebo group, respectively. Compared with patients treated with surgery alone, patients receiving adjuvant anlotinib combined with surgery had a reduced risk of disease recurrence [HR, 0.47; 95% confidence interval (CI), 0.22–1.00; P = 0.0445]. Based on the tumor histology, the reduced risk of disease recurrence with anlotinib versus placebo was observed in patients with myxofibrosarcoma (HR, 0.54; 95% CI, 0.17–1.65; P = 0.2698) and undifferentiated pleomorphic sarcoma (HR, 0.58; 95% CI, 0.12–2.87; P = 0.4971). Four patients discontinued anlotinib: two for proteinuria/hematuria (2/44, 5%) and two for poor healing of surgical wound (2/44, 5%).Conclusions:Compared with surgery alone, adjuvant anlotinib following surgery reduces the incidence of disease relapse in localized high-grade STS, with acceptable toxicity.
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Anlotinib versus Placebo as Adjuvant Therapy for Localized High-Grade Soft-Tissue Sarcomas: A Phase II, Double-Blinded, Randomized Controlled Trial
Supplementary Table S1. Representativeness of Study Participants.
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Anlotinib versus Placebo as Adjuvant Therapy for Localized High-Grade Soft-Tissue Sarcomas: A Phase II, Double-Blinded, Randomized Controlled Trial
Supplementary Table S1. Representativeness of Study Participants.